P1: PSB Printer: Yet To Come
9780521704632ind CUFX213A/Peck 9780521618168 December 29, 2007 17:19
369 Index5-HT 3 antagonists, 290 –291
5-HT 3 receptor, 26
hydralazine, 255 –256
effects, 255 –256
mechanism of action, 255
presentation, 255
uses, 255
hydrocortisone, perioperative
supplementation, 355
hydrolysis, 17 –18
hydroxyethyl starches,301t, 303t
hyoscine, 287 –288
hyperbolic function, 54
hyperkalaemia
aldosterone antagonists, 308 –309
bicarbonate,304t
calcium salts, 216
digoxin induced, 232 –233
potassium-sparing diuretics, 308
suxamethonium-induced, 181
hyperthryoidism, drug use, 357 –358
hypnotics, 270 –274
non-benzodiazepine, 274
hypoalbuminaemia,7, 303t
hypoglycaemic agents, 347 –352
acarbose, 350
biguanides, 350
meglitinides, 351
sulphonylureas, 348 –349
thiazolidinediones, 350 –351
see alsoinsulin
hypokalaemia, thiazides with digoxin, 306 –307
hypothalamus, 197ibuprofen, 158
imidazoles, 94 , 332–333
imipenem, 317
imipramine, 274 –276
indomethacin, 157
infants, 22 –23
infected tissue, local anaesthetics, 166
inflammation, protein binding, 7
infusion rate, 75 –76
inhalation route, 13
local site of action, 13
systemic site of action, 13
inhaled anaesthetics, 114 –115
alveolar ventilation, 116
biochemical characteristics, 115
blood–brain barrier crossing, 15
blood:gas partition coefficient, 116 –117
cardiac output, 116
cardiovascular effects,128t
concentration, 117
ideal, 114kinetics, 115 –117
metabolism, 117 , 117t
partial pressure, 114 , 116
pharmacology, 117 , 128t
physical characteristics, 115
physiochemical properties,125t
physiological effects,129t
respiratory effects,128t
structure,133f
see alsoinspired concentration; minimum
alveolar concentration (MAC)
inositol triphosphate (IP 3 ), 28–30
inotropic agents, 212 –216
inspired concentration, 116 , 116f
insulin, 347 –348
blood–brain barrier crossing, 15
copreparation with zinc/protamine, 12
interaction with dextrose, 40
physiology, 347
preparations, 347 –348
sensitivity, 350 –351
side-effects, 348
sliding scale, 352
synthesis,348f
insulin receptor, 30 –31
integration,60f, 62–63
intensive care, nitric oxide use in adults,131t,
132t
intermediate messengers, 26 –31
intermittent boluses, accumulation of drug,
76f
international normalized ratio (INR), 22 ,
344
interstitial volume, 298
intestinal mucosa
active transport, 3
tight junctions, 1
intracellular sequestration, 72
intracellular volume, 298
intramuscular route, 11 –12
intra-ocular pressure,
suxamethonium-induced,
181 –182
intrathecal route, 14
intravascular volume, 298
intravenous administration, 8
regional anaesthesia, 168
intravenous anaesthetics, 102 –114
barbiturates, 103 –108
blood–brain barrier crossing, 15
chemical structure,113f
ideal agents, 103
non-barbiturates, 108 –114
pharmacokinetics,109t
pharmacological properties,114t